Assessment of the effect of adalimumab on response to influenza virus and pneumococcal vaccines in subjects with rheumatoid arthritis

Trial Profile

Assessment of the effect of adalimumab on response to influenza virus and pneumococcal vaccines in subjects with rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Adalimumab (Primary) ; Influenza virus vaccine; Pneumococcal vaccines
  • Indications Influenza virus infections; Pneumococcal infections; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
    • 16 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top